Cutaneous Allodynia Associated With GLP-1RA Tirzepatide for Weight Management: A Case Series

08 May 2026 : Case report USA

Unknown etiology, Challenging differential diagnosis, Unusual or unexpected effect of treatment, Adverse events of drug therapy

Madhu Parna Chakrabarti

^{ABCDEF 1*}, Steven Han

^{BDE 2}, Natasha M. Campbell^{ACDE 2}

DOI: 10.12659/AJCR.952158

Am J Case Rep 2026; 27:e952158

Authors information Article notes Copyright and License information

Introduction Case Reports Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 2 Laboratory values of 2 patients treated with tirzepatide who experienced allodynia.

Laboratory tests	Patient 1			Patient 2			Reference ranges
Laboratory tests	Baseline	After allodynia onset	After allodynia resolution	Baseline	After allodynia onset	After allodynia resolution	Reference ranges
BUN	15	14	12	17	28	21	9–23 mg/dL
Creatinine	0.85	0.79	0.87	1.29	1.18	1.23	0.55–1.02 mg/dL
eGFR mL/min	≥60	≥60	≥60	≥60	≥60	≥60	≥60 mL/min/1.73 m
AST	23	19	20	52	60	48	0–34 U/L
ALT	38	26	26	47	41	41	10–49 U/L
Bilirubin	0.6	0.4	0.4	0.6	1.0	0.8	0.2–1.3 mg/dL
HbA1c	5.7%	5.3%	5.4%	5.2%	N/A	N/A	<5.7%
Sodium	140	139	139	136	134	139	136–145 mmol/L
Potassium	4.7	3.5	3.8	4.3	3.9	4.5	3.5–5.1 mmol/L
Calcium	9.3	9.3	8.6	9.2	9.2	9.2	8.7–10.4 mg/dL
TSH	3.640	4.504	N/A	1.210	N/A	1.200	0.550–4.780 uIU/mL
Vitamin B12	N/A	719	N/A	1118	N/A	N/A	211–911 pg/mL
Vitamin D	15.8	13.0	N/A	45.8	N/A	N/A	30–100 ng/mL
Hemoglobin	14.2	13.0	13.7	15.9	17.6	17.2	12–16 g/dL
Leukocyte count	6.4	7.6	6.6	5.1	4.6	3.7	4.5–11.0×10/μL
Absolute neutrophil count	3.5	4.5	N/A	2.3	2.8	1.9	1.8–8.0×10/μL
Eosinophil percentage	3.6%	3%	N/A	2%	2%	2%	0.0–9.0%
Platelet count	348	317	344	184	175	182	140–450×10/μL
AST – aspartate transaminase; ALT – alanine transaminase; BUN – blood urea nitrogen; eGFR – estimated glomerular filtration rate; HbA1c – glycosylated hemoglobin; TSH – thyroid-stimulating hormone.

Back to the Article